Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Points - Intellia Therapeutics awarded inducement grants to six new employees as part of its 2024 Inducement Plan on October 1, 2025 [1] - The inducement grants consist of time-based restricted stock units (RSUs) totaling 65,200 shares, with vesting occurring over three years [2] - The awards were granted outside of Intellia's stockholder-approved equity incentive plans and were approved as a material inducement for employment [3] Company Overview - Intellia Therapeutics is a clinical-stage gene editing company focused on CRISPR-based therapies aimed at addressing unmet medical needs [4] - The company leverages gene editing technology to develop novel medicines and is committed to advancing treatment paradigms for patients [4] - Intellia is expanding its CRISPR-based platform with new editing and delivery technologies to maximize the potential of gene editing [4]